CN109219607B - 二肽基肽酶-iv抑制剂的丁二酸盐的晶型 - Google Patents
二肽基肽酶-iv抑制剂的丁二酸盐的晶型 Download PDFInfo
- Publication number
- CN109219607B CN109219607B CN201780032328.3A CN201780032328A CN109219607B CN 109219607 B CN109219607 B CN 109219607B CN 201780032328 A CN201780032328 A CN 201780032328A CN 109219607 B CN109219607 B CN 109219607B
- Authority
- CN
- China
- Prior art keywords
- compound
- degrees
- methyl
- crystal form
- succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
混合溶剂 | 溶剂1 | 溶剂2 |
1 | 甲基异丁酮 | 乙醚 |
2 | 二甲苯 | 乙醚 |
3 | 乙酸异丁酯 | 乙醚 |
4 | 乙醚 | 乙醚 |
5 | 1,4-二氧六环 | 戊烷 |
6 | 1,4-二氧六环 | 庚烷 |
7 | 1,4-二氧六环 | 环己烷 |
8 | 1,4-二氧六环 | 甲基异丁酮 |
9 | 1,4-二氧六环 | 二甲苯 |
10 | 1,4-二氧六环 | 乙酸异丁酯 |
11 | 乙酸丁酯 | 乙醚 |
12 | 乙酸丁酯 | 1,4-二氧六环 |
投料量 | 溶剂及比例 |
2mL | 四氢呋喃 |
3mL | 丙酮 |
5.5mL | 乙腈∶水=10∶1 |
2mL | 甲醇 |
4mL | 乙醇 |
1mL | 乙醇∶水=10∶1 |
2mL | 异丙醇∶水=19∶1 |
2mL | 异丙醇∶水=9∶1 |
样品名称 | pH值 |
式(1)化合物的二盐酸盐晶型I | 2.0 |
式(1)化合物的丁二酸盐晶型I | 4.8 |
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016104111267 | 2016-06-08 | ||
CN201610411126 | 2016-06-08 | ||
PCT/CN2017/087433 WO2017211293A1 (zh) | 2016-06-08 | 2017-06-07 | 二肽基肽酶-iv抑制剂的丁二酸盐的晶型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109219607A CN109219607A (zh) | 2019-01-15 |
CN109219607B true CN109219607B (zh) | 2021-03-30 |
Family
ID=60578368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780032328.3A Active CN109219607B (zh) | 2016-06-08 | 2017-06-07 | 二肽基肽酶-iv抑制剂的丁二酸盐的晶型 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109219607B (zh) |
WO (1) | WO2017211293A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102127072A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
CN102863440A (zh) * | 2011-07-09 | 2013-01-09 | 山东轩竹医药科技有限公司 | 二肽基肽酶-iv抑制剂的盐的晶型 |
WO2013046229A1 (en) * | 2011-09-26 | 2013-04-04 | Hetero Research Foundation | Novel salts of alogliptin |
-
2017
- 2017-06-07 WO PCT/CN2017/087433 patent/WO2017211293A1/zh active Application Filing
- 2017-06-07 CN CN201780032328.3A patent/CN109219607B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102127072A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
WO2011085643A8 (zh) * | 2010-01-15 | 2012-07-05 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
CN102863440A (zh) * | 2011-07-09 | 2013-01-09 | 山东轩竹医药科技有限公司 | 二肽基肽酶-iv抑制剂的盐的晶型 |
WO2013046229A1 (en) * | 2011-09-26 | 2013-04-04 | Hetero Research Foundation | Novel salts of alogliptin |
Non-Patent Citations (1)
Title |
---|
《Discovery of Imigliptin,a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes》;SHU,Chutian 等;《ACS Medicinal Chemistry Letters》;20140616;第5卷(第8期);第921–926页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109219607A (zh) | 2019-01-15 |
WO2017211293A1 (zh) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9518059B2 (en) | Inhibitor crystalline form and preparation method and use thereof | |
EP3610875B1 (en) | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof | |
RU2577334C2 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА МОНОГИДРАТА ГИДРОХЛОРИДА (R)-7-ХЛОР-N-(ХИНУКЛИДИН-3-ИЛ)БЕНЗО[b]ТИОФЕН-2-КАРБОКСАМИДА | |
JP2021500340A (ja) | PI3K−γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
CN104803971B (zh) | 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物 | |
WO2009016653A1 (en) | Stable polymorphic form of paliperidone and process for its preparation | |
CN108884099B (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
US8349863B2 (en) | Crystalline polymorphic form of a camptothecin analogue | |
CN108779122B (zh) | 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法 | |
CN109219607B (zh) | 二肽基肽酶-iv抑制剂的丁二酸盐的晶型 | |
RU2719484C2 (ru) | Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма | |
CN106349216B (zh) | 化合物A的晶型α及其制备方法和含有该晶型的药物组合物 | |
CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
CN113999211B (zh) | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 | |
CN108602817B (zh) | 二肽基肽酶-iv抑制剂的苯甲酸盐的晶型 | |
JP6761564B2 (ja) | ナトリウム・グルコース共輸送体2阻害薬のl−プロリン化合物、およびl−プロリン化合物の一水和物および結晶 | |
CN101622257B (zh) | N-{2-氟-5-[3-(噻吩-2-羰基)-吡唑并[1,5-a]嘧啶-7-基]-苯基}-N-甲基-乙酰胺的多晶型B | |
CN113045554A (zh) | 一种非索替尼晶型及其制备方法 | |
Łaszcz et al. | Structural and physicochemical studies of olopatadine hydrochloride conformational polymorphs | |
CN102746227A (zh) | 一种磷酸二甲啡烷晶型ⅱ及制备方法和药物组合物 | |
CN107849051B (zh) | 取代的氨基吡喃衍生物的晶型 | |
WO2022143897A1 (zh) | A-失碳-5α雄甾烷化合物的多晶型物 | |
TW201904972A (zh) | 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法 | |
WO2020073985A1 (zh) | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 | |
CA3084848A1 (en) | Crystal form of renal outer medullary potassium channel inhibitor and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191025 Address after: Room 510, building 2, No. 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing 100176 Applicant after: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 2518 Applicant before: XUANZHU PHARMA Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200924 Address after: 135000 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province Applicant after: Jilin Huisheng biopharmaceutical Co.,Ltd. Applicant after: Beijing huizhiheng Biotechnology Co.,Ltd. Address before: Room 510, building 2, No. 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing 100176 Applicant before: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 135007 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province Patentee after: Jilin Huisheng Biopharmaceutical Co.,Ltd. Patentee after: Beijing huizhiheng Biotechnology Co.,Ltd. Address before: NO.666 Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province Patentee before: Jilin Huisheng biopharmaceutical Co.,Ltd. Patentee before: Beijing huizhiheng Biotechnology Co.,Ltd. |